Paroxetine in the treatment of chronic posttraumatic stress disorder: Results of a placebo-controlled, flexible-dosage trial

Journal of Clinical Psychiatry

Volumn 62, Issue 11, 2001, Pages 860-868

  Tucker, P ^a   Zaninelli, R ^a   Yehuda, R ^a   Ruggiero, L ^a   Dillingham, K ^a   Pitts, C D ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; BROFAROMINE; CLONAZEPAM; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FAMILY LIFE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REMISSION; SOCIAL LIFE; TREATMENT OUTCOME; WORK;

EID: 0035196193     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v62n1105     Document Type: Article

References (47)

1. Posttraumatic stress disorder in the National Comorbidity Survey
2. Traumatic events and posttraumatic stress disorder in an urban population of young adults
3. Sexual assault and psychiatric disorders among a community sample of women
4. Community patterns of posttraumatic stress disorders
5. Trauma: Prevalence, impairment, service use, and cost
6. Posttraumatic stress disorder: Epidemiology and health-related considerations
7. Posttraumatic stress disorder: The burden to the individual and to society
8. Suicidal behavior after severe trauma, pt 1: PTSD diagnoses, psychiatric comorbidity, and assessments of suicidal behavior
9. Cortisol alterations in PTSD
10. Psychoneuroendocrinology of post-traumatic stress disorder
11. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine
12. Treatment of posttraumatic stress disorder with amitriptyline and placebo
13. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder
14. Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic
15. A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder
16. Treatment of recent trauma survivors with benzodiazepines: A prospective study
17. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment
18. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder
19. Fluoxetine in posttraumatic stress disorder
20. Fluoxetine in posttraumatic stress disorder: Randomized, double-blind study
21. Symptom-specific effects of fluoxetine in post-traumatic stress disorder
22. The development of clinician-administered PTSD scale
23. Clinician-administered PTSD scale: A review of the first ten years of research
24. Efficacy and safety of sertraline treatment of posttraumatic stress disorder
25. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder
26. A study comparing paroxetine, placebo and imipramine in depressed patients
27. A comparison of paroxetine and placebo in depressed outpatients
28. Paroxetine treatment of generalized social phobia
29. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder
30. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder
31. Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial
32. An open trial of paroxetine in patients with noncombat-related chronic PTSD
33. Paroxetine versus cognitive-behavioural therapy in the treatment of depression in PTSD patients
34. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structure interview: Reliability and validity according to the CIDI
35. Assessment of a new self-rating scale for posttraumatic stress disorder
36. Further psychometric assessment of the TOP-8: A brief interview-based measure of PTSD
37. The measurement of disability
38. A new depression scale designed to be sensitive to change
39. Clinical guidelines for establishing remission in patients with depression and anxiety
40. Efficacy and safety of paroxetine treatment of chronic PTSD: A fixed dosage, placebo-controlled study
41. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder
42. Modulation of noradrengeric firing by selective serotonin reuptake blockers
43. Paroxetine treatment of GAD: A double-blind, placebo-controlled trial
44. Lack of efficacy for fluoxetine in PTSD: A placebo controlled trial in combat veterans
45. Sertraline treatment of posttraumatic stress disorder: Results of 24 weeks of open-label continuation treatment